Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Assay to support the diagnosis of autoimmune diseases - 22/06/2022 Immunkomplexe_sIC-assay_Teaser.jpg

    Tracking down pathogenic immune complexes

    Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tracking-down-pathogenic-immune-complexes
  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Press release - 13/08/2021

    Paradigm shift in immunology 'Adaptive Tolerance' balances autoimmune reaction

    Immunologists at Ulm University and its Medical Centre have developed a new model that could revolutionise the treatment of autoimmune disease as well as vaccine development. As 'Adaptive Tolerance' demonstrates, autoreactive antibodies are by no means disease drivers which a healthy organism swiftly eliminates. Rather, they trigger the formation of a class of antibodies that protect the body's own structures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/paradigm-shift-immunology-adaptive-tolerance-balances-autoimmune-reaction
  • Review article (new edition) - 08/07/2020 Arm in den mithilfe einer Spritze eine Impfung gespritzt wird.

    Immunology – at the forefront of medical progress

    Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
  • Multiple sclerosis - 12/03/2020 Anatomie_des_menschlichen_Kopfes.jpg

    Direct application of biopharmaceuticals through the nose into the brain

    There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain
  • Press release - 23/05/2017

    TolerogenixX secures seed funding and completes Phase I clinical trial

    TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tolerogenixx-secures-seed-funding-and-completes-phase-i-clinical-trial
  • Personalised Medicine - 04/05/2017 BigData-Onkologie-doehner_hartmut_eberhardt_kiz.jpg

    Big data make therapy work better

    An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren
  • Article - 22/12/2014 Schematic showing T-cell activation without and without CTLA4.

    The immune system – both weak and overreactive in the absence of CTLA4

    The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London scientists Desire Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency CCI at the Freiburg…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immune-system-both-weak-and-overreactive-in-the-absence-of-ctla4
  • Article - 13/01/2014 The photo shows vials with caps, arranged in two rows.

    DIARECT AG – development and production of immunodiagnostics components

    Founded by Dr. Heinz Haubruck and Prof. Dr. Bodo Liedvogel in 1998, the biotechnology company DIARECT AG (DIAgnostic by RECombinant Technology) from Freiburg sells tried and tested and new products. The company produces proteins, nucleoproteins and assay components for the diagnostics sector. These products enable the reliable identification of autoimmune disorders and infectious diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/diarect-ag-development-and-production-of-immunodiagnostics-components
  • Article - 12/11/2012 18619_de.jpg

    Autoimmune diseases – when the body sheds its skin

    Most people believe that snakes and insects are the only animals able to shed their skin. However autoimmune diseases of the largest human organ i.e. the skin can have a similar effect by creating blisters scars peeling and wet wounds. Dr. Cassian Sitaru from the University of Freiburg Medical Centre specifically focuses on blistering autoimmune dermatoses. Using disease models in Petri dishes and laboratory mice Sitaru and his team hope to find…

    https://www.gesundheitsindustrie-bw.de/en/article/news/autoimmune-diseases-when-the-body-sheds-its-skin
  • Article - 12/12/2011 15942_de.jpg

    Rheumatoid arthritis biomarkers

    A plethora of biomarkers is available for the early diagnosis of rheumatoid arthritis and associated tissue damage and disorders. In addition, new biomarkers that improve the diagnosis and treatment of patients suffering from this common destructive autoimmune disease are constantly being discovered.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rheumatoid-arthritis-biomarkers
  • Press release - 30/11/2011 15922_de.jpg

    Researchers are challenging a common model of immunology

    Up to now, scientists have assumed that mast cells, a certain type of immune cells, play a central role in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Current studies conducted at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now provided evidence to refute this assumption. Now it is only the mast cells’ central function in allergies that remains undisputed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-are-challenging-a-common-model-of-immunology
  • Press release - 12/10/2011 Logo DKFZ, blue letters "DKFZ"

    Autoimmune Diseases Affect Cancer Risk

    In a recently published study, scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have calculated the interrelations between autoimmune diseases and cancer of the digestive tract. They discovered that many autoimmune diseases increase the cancer risk, while others, such as rheumatism, are associated with a significantly lower bowel cancer risk. These differing impacts on cancer risk may be attributable to the…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/autoimmune-diseases-affect-cancer-risk
  • Press release - 05/03/2011

    Research prize for the gene therapy of rare diseases

    The Eva Luise and Horst Köhler Foundation for People with Rare Diseases has awarded the 2011 Eva Luise Köhler Research Prize, which includes prize money of 50,000 euros, to an interdisciplinary team of researchers: Professor Dr. Christoph Klein, Department of Paediatric Haematology and Oncology at the Hannover Medical School (MHH), Professor Dr. Christopher Baum, Department of Experimental Haematology (MHH), Professor Dr. Christoph von Kalle,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-prize-for-the-gene-therapy-of-rare-diseases
  • Article - 28/02/2011 13790_de.jpg

    Rare fever syndromes provide insights into the anti-inflammatory effect of therapies

    Quite a few people suffer lifelong regularly occurring fever and inflammation attacks with no apparent reason. The identification of the genetic causes of the syndromes has in the meantime led to the identification of the metabolic pathway involved as well as to targeted therapies. Effective treatment has greatly improved sufferers quality of life.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rare-fever-syndromes-provide-insights-into-the-anti-inflammatory-effect-of-therapies
  • Article - 28/02/2011 13779_de.jpg

    Development of food allergies

    Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
  • Article - 11/12/2010 13236_de.jpg

    Opportunities, benefits and risks are not so different from each other

    Adverse drug reactions that compromise the safety of drugs do not necessarily mean that the development of a pharmaceutically active agent is immediately stopped. The case of a pharmaceutical agent initially developed by Tübingen-based c-a-i-r biosciences GmbH shows how an undesired event can actually lead to new opportunities. The original agent is now being further developed on a different basis from the original plans.

    https://www.gesundheitsindustrie-bw.de/en/article/news/opportunities-benefits-and-risks-are-not-so-different-from-each-other
  • Press release - 11/03/2010 Cellzome Logo

    Cellzome Announces Second Alliance with GlaxoSmithKline

    Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome’s proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellzome-announces-second-alliance-with-glaxosmithkline
  • Article - 28/11/2009 Two men sitting at a table.

    "You cannot afford to fail twice in Germany"

    Prof. Dr. Bodo Liedvogel and Dr. Heinz Haubruck founded the company DIARECT AG in Freiburg in 1998. They not only brought 20 years of experience in industry to the company but also their entire savings. In the following interview Dr. Heinz Haubruck tells Christoph Bächtle about the return investors expect from companies how to win over potential clients and the risks associated with setting up ones own business.

    https://www.gesundheitsindustrie-bw.de/en/article/news/you-cannot-afford-to-fail-twice-in-germany
  • Press release - 30/06/2009 08933_de.jpg

    Gentle rather than radical: ways to improve the treatment of autoimmune diseases

    Autoimmune diseases are usually treated with drugs that block the entire immune system rendering the body very susceptible to all kinds of infections. A team of Constance researchers under the leadership of Prof. Marcus Groettrup has developed a treatment method that only targets part of the immune system and is therefore far better tolerated by patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gentle-rather-than-radical-ways-to-improve-the-treatment-of-autoimmune-diseases
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search